Oksana Suchowersky

Best Publications

• Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial

  R. Holloway;I. Shoulson;K. Kieburtz;M. McDermott

  1262
  Citations

• Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology

  J. M. Miyasaki;W. Martin;O. Suchowersky;W. J. Weiner

  556
  Citations

• CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

  J.-M. Lee;E.M. Ramos;J.-H. Lee;T. Gillis

  449
  Citations

• Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology

  O. Suchowersky;S. Reich;J. Perlmutter;T. Zesiewicz

  367
  Citations

• The Canadian multicentre study of deep brain stimulation for cervical dystonia.

  Zelma H. T. Kiss;Kristina Doig-Beyaert;Michael Eliasziw;Joseph Tsui

  338
  Citations

• Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology

  O. Suchowersky;G. Gronseth;J. Perlmutter;S. Reich

  310
  Citations

• SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis.

  Guy A. Rouleau;Arthur W. Clark;Karen Rooke;Albena Pramatarova

  293
  Citations

• Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk.

  Marlene Huggins;Maurice Bloch;Sandi Wiggins;Shelin Adam

  290
  Citations

• Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period

  G-Y.R. Hsiung;S.K. Das;R. Ranawaya;A.-L. Lafontaine

  271
  Citations

• Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease

  I H Richard;R Kurlan;C Tanner;S Factor

  267
  Citations

• Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.

  Hubert H. Fernandez;David G. Standaert;Robert A. Hauser;Anthony E. Lang

  262
  Citations

• Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease

  Cory Toth;Kim Breithaupt;Shaohua Ge;Yanjun Duan

  236
  Citations

• Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease

  L. Djoussé;B. Knowlton;M. Hayden;E. W. Almqvist

  216
  Citations

• A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS Study

  Jian Liang Li;Michael R. Hayden;Elisabeth W. Almqvist;Ryan R. Brinkman

  196
  Citations

• Mutations in BICD2, which Encodes a Golgin and Important Motor Adaptor, Cause Congenital Autosomal-Dominant Spinal Muscular Atrophy

  Kornelia Neveling;Lilian A. Martinez-Carrera;Irmgard Hölker;Angelien Heister

  185
  Citations

• Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.

  Mei Sun;Jeanne C. Latourelle;G. Frederick Wooten;Mark F. Lew

  179
  Citations

• Relationship between trinucliotide repeats and neuropathological changes in Huntington's diease

  Sarah Furtado;Oksana Suchowersky;N. Barry Rewcastle;Lisa Graham

  179
  Citations

• Impairment of pronation, supination, and body co-ordination in reach-to-grasp tasks in human Parkinson's disease (PD) reveals homology to deficits in animal models.

  Ian Q Whishaw;Oksana Suchowersky;Oksana Suchowersky;Leigh Davis;Justyna Sarna

  169
  Citations

• Nursing time to program and assess deep brain stimulators in movement disorder patients.

  Karen Hunka;Oksana Suchowersky;Susan Wood;Lorelei Derwent

  167
  Citations

• Canadian Guidelines on Parkinson's Disease.

  David Grimes;Joyce Gordon;Barbara Snelgrove;Ivy Lim-Carter

  160
  Citations